Nebivolol: A Third-Generation β-Blocker That Augments Vascular Nitric Oxide Release
Why the study?
Do in vivo metabolites of nebivolol increase vascular nitric oxide production in mouse thoracic aorta segments?
Population
Mouse thoracic aorta segments and in vivo mouse models
Comparison
Nebivolol and its in vivo metabolites vs Unmetabolized nebivolol, coadministration of…
Design
Preclinical
Authors
Discussion
Loading...
Member takes
Implication
Hypothesis-generating for nebivolol metabolite effects on vascular NO; human studies needed before any clinical relevance.
Structured PICO
Do in vivo metabolites of nebivolol increase vascular nitric oxide production in mouse thoracic aorta segments?
P
Population
Mouse thoracic aorta segments and in vivo mouse models
I
Intervention
Nebivolol and its in vivo metabolites (plasma from mice treated with nebivolol)
C
Comparator
Unmetabolized nebivolol, coadministration of butoxamine (selective beta2-adrenergic receptor antagonist), or absence of calcium
O
Outcome
Vascular nitric oxide (NO) productionsurrogate
In vivo metabolized nebivolol increases vascular NO production via endothelial beta2-adrenergic receptor ligation and subsequent calcium-dependent endothelial NO synthase activation.
Cite This Study
Broeders et al. (2000) studied this question.